![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 9633f CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 26th May 1998 For Further information contact: Cambridge Antibody Technology Group Plc Dr David Chiswell, Chief Executive Officer Tel: +44 (0) 1763 263233 John Aston, Finance Director City/Financial Enquiries HCC.De Facto Financial, Nicola How Tel: +44 (0) 171 957 4600 Trade/Scientific Press Enquiries HCC.De Facto Cambridge, Andrew Worsfold Tel: +44 (0) 1223 518093 CAT'S MONOCLONAL ANTIBODY APPROVED TO ENTER CLINICAL TRIALS FOR GLAUCOMA SURGERY Medicines Control Agency approves human anti-TGFb2 antibody to enter UK Phase I/IIa clinical trials Melbourn, UK... Cambridge Antibody Technology (CAT) announced today that it has obtained regulatory approval from the Medicines Control Agency (MCA) to begin UK Phase I/IIa clinical trials with its human anti-TGFb2 monoclonal antibody in patients undergoing glaucoma filtration surgery. The anti-TGFb2 monoclonal antibody is both potent and specific in neutralising TGFb2, the cytokine molecule believed to be responsible for fibrosis or scarring in and around the eye following surgery for the treatment of glaucoma. Scarring is the main cause of failure of such surgery. CAT estimates that at least 250,000 patients could benefit from this treatment in the USA and Western Europe alone. The trials will initially involve 24 patients and will be carried out at two major ophthalmology centres in the UK. Pre clinical results with this antibody were presented earlier this month at ARVO '98 (The Association for Research in Vision and Ophthalmology), the world's largest eye research meeting. These results showed potent activity against scarring after experimental glaucoma surgery, and in a model for proliferative vitreoretinopathy (PVR), for which Phase I/IIa trials have already begun. Peng Khaw, Consultant Glaucoma Surgeon at Moorfields Eye Hospital and Director of the Wound Healing Unit at the Institute of Ophthalmology in London added, "We have already conducted a series of experiments in our laboratories with this antibody, all with encouraging results. We are optimistic for its prospects in patients undergoing glaucoma surgery - the product is addressing a real medical need." Notes to Editors: 1. CAT is a UK biotechnology company focussed on engineering advanced human monoclonal antibodies for drug discovery and drug development. Based on the Melbourn Science Park, 10 miles south of Cambridge, England, CAT currently employs over 130 people. In March 1997, CAT completed its initial public offering and listed on the London Stock Exchange raising approximately #41 million. CAT has a world-leading platform technology for rapidly isolating human monoclonal antibodies and its CAT phage-display library currently incorporates more than 67 billion distinct antibodies. This library forms the basis for the company's strategy to develop a broad-range of antibody-based therapeutics and for discovering new drug leads using functional genomics. The first two antibody products developed by CAT started clinical trials in 1997, in inflammation and fibrosis. CAT plans to develop a portfolio of clinical development programmes with the objective of initiating three to four clinical programmes per year from the year 2000. CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies. Currently, these include: ICOS, Genentech, Pfizer, Eli Lilly, BASF/Pharma, Genetics Institute/BASF Pharma, Mitsubishi Chemical and ObeSys (with BTG). 2. Glaucoma is characterised by raised intra-ocular pressure which jeopardises eyesight. It is estimated to affect six million people in North America and Western Europe. A conservative estimate is that at least 250,000 glaucoma filtration operations per year in the US and Western Europe could benefit from this antibody since fibrosis or scarring is the main cause of failure of surgery. 3. CAT's anti-TGFb2 monoclonal antibody for the prevention of PVR entered clinical trials in November 1997. PVR is characterised by the formation of fibrous tissue in, and in front of, the retina following trauma, retinal detachment or in the late stages of diabetic retinopathy. END MSCSELSWMUAUFLI
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions